In this episode of Medtech Talk, host Geoff Pardo and Eric Wichems, former CEO of Vertos Medical (recently acquired by Stryker), discuss the responsibilities of a CEO, why high accountability and transparency are important aspects of company culture, and how to hire the right person for the position—and how to determine if they can thrive in your company’s culture. Wichems shares his background in engineering and how he found his way to Vertos, as well as his thoughts on the Stryker acquisition and the reasons behind it.

Medtech Talk Links:
Cambridge Healthtech Institute
Medtech Talk
Gilde Healthcare

Vertos Medical:
Vertos Medical

Stryker:
Stryker Interventional Spine

In this month’s Medtech Talk, co-host Swaril Mathur, vice president of business development at Axonics, debuts in her first episode with John Woock, former EVP and chief marketing and strategy officer at Axonics. They discuss the early days of their company, including what motivated Woock to join a company that was considered risky at the time, what he learned from supporting and working directly with the field team, and how Axonics handled the early stages of commercial launch during the pandemic. Woock also reflects on how much the company has changed over the years in its culture and leadership, including the decisions that felt good and the ones that were harder to grapple with.

Medtech Talk Links:
Cambridge Healthtech Institute
Medtech Talk
Gilde Healthcare

Axonics Links:
Axonics

This month at Medtech Talk, co-host Justin Klein, co-founder and managing partner at Vensana Capital, debuts in his first episode with a discussion with Douglas Kelly, former deputy center director for science and chief scientist at the Center for Devices and Radiological Health at the FDA. Kelly talks about his time at the FDA and the fundamental changes he implemented to make a helpful impact on patients, including when the pandemic was at its peak. Kelly also shares his thoughts on the value of fostering innovation and the importance of breakthrough designation, as well as how to approach the process of advocacy and get in better alignment with shared priorities with the FDA, CMS, and other stakeholders